ピロリ菌のCYP2C19および23S rRNAの多型に基づくピロリ菌感染症の個別化治療

基本情報

NCT ID: NCT00149084
ステータス: 不明
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 296
治験依頼者名: Hamamatsu University

概要

The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor \[PPI\], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.

対象疾患

Helicobacter InfectionsGastritisGastric UlcerDuodenal Ulcer

介入

Lansoprazole, clarithromycin, amoxicillin(DRUG)

依頼者（Sponsor）

Hamamatsu University(OTHER)

Yokoyama Foundation For Clinical Pharmacology(OTHER)

実施施設 (1)

浜松医科大学医学部附属病院

Hamamatsu, Shizuoka, Japan(RECRUITING)